Milbemycins: more than efflux inhibitors for fungal pathogens

Autor: Patrick Vandeputte, Maurizio Sanguinetti, Bertrand Rochat, Luis Vale Silva, Dominique Sanglard, Riccardo Torelli
Přispěvatelé: Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA)
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Azoles
Antifungal Agents
[SDV]Life Sciences [q-bio]
Drug Resistance
ATP-binding cassette transporter
Candida glabrata
Drug resistance
Mice
Gene Expression Regulation
Fungal

Oximes
Pharmacology (medical)
Candida albicans
Fluconazole
Inbred BALB C
Anthelmintics
0303 health sciences
Mice
Inbred BALB C

biology
Candidiasis
Corpus albicans
Infectious Diseases
Fungal
Female
Efflux
Macrolides
medicine.drug
Genes
Fungal

Microbial Sensitivity Tests
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
Microbiology
03 medical and health sciences
Drug Resistance
Fungal

medicine
Animals
Mechanisms of Action: Physiological Effects
030304 developmental biology
Pharmacology
030306 microbiology
Gene Expression Profiling
Membrane Transport Proteins
biology.organism_classification
Protein ubiquitination
Gene Expression Regulation
Genes
ATP-Binding Cassette Transporters
candida albicans
Reactive Oxygen Species
Milbemycins
Zdroj: Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (2), pp.873-386. ⟨10.1128/AAC.02040-12⟩
ISSN: 0066-4804
1098-6596
DOI: 10.1128/AAC.02040-12⟩
Popis: Existing antifungal agents are still confronted to activities limited to specific fungal species and to the development of resistance. Several improvements are possible either by tackling and overcoming resistance or exacerbating the activity of existing antifungal agents. In Candida glabrata , azole resistance is almost exclusively mediated by ABC transporters (including C. glabrata CDR1 [ CgCDR1 ] and CgCDR2 ) via gain-of-function mutations in the transcriptional activator CgPDR1 or by mitochondrial dysfunctions. We also observed that azole resistance was correlating with increasing virulence and fitness of C. glabrata in animal models of infection. This observation motivated the re-exploitation of ABC transporter inhibitors as a possible therapeutic intervention to decrease not only the development of azole resistance but also to interfere with the virulence of C. glabrata . Milbemycins are known ABC transporter inhibitors, and here we used commercially available milbemycin A3/A4 oxim derivatives to verify this effect. As expected, the derivatives were inhibiting C. glabrata efflux with the highest activity for A3 oxim below 1 μg/ml. More surprising was that oxim derivatives had intrinsic fungicidal activity above 3.2 μg/ml, thus highlighting effects additional to the efflux inhibition. Similar values were obtained with C. albicans . Our data show that the fungicidal activity could be related to reactive oxygen species formation in these species. Transcriptional analysis performed both in C. glabrata and C. albicans exposed to A3 oxim highlighted a core of commonly regulated genes involved in stress responses, including genes involved in oxidoreductive processes, protein ubiquitination, and vesicle trafficking, as well as mitogen-activated protein kinases. However, the transcript profiles contained also species-specific signatures. Following these observations, experimental treatments of invasive infections were performed in mice treated with the commercial A3/A4 oxim preparation alone or in combination with fluconazole. Tissue burden analysis revealed that oxims on their own were able to decrease fungal burdens in both Candida species. In azole-resistant isolates, oxims acted synergistically in vivo with fluconazole to reduce fungal burden to levels of azole-susceptible isolates. In conclusion, we show here the potential of milbemycins not only as drug efflux inhibitors but also as effective fungal growth inhibitors in C. glabrata and C. albicans .
Databáze: OpenAIRE